Cornerstone achievement supports global growth strategy

MARKHAM, ON, June 19, 2017 /CNW/ - MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 certified cannabis producer, announced today that it has become the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices ("ICH-GMP") for Active Pharmaceutical Ingredients.

MedReleaf's wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility.

Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada, the United States, EU, Japan, Singapore and Australia.

MedReleaf's ICH-GMP certification will support the Company's international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, including:

Providing the Company with a global manufacturing practice and platform that complies with GMP requirements around the world.

Facilitating the sale of MedReleaf products to any global market allowing the import of medical cannabis.

Accelerating MedReleaf's partnerships with pharmaceutical and biotech companies as the only ICH-GMP certified producer of medical cannabis that can be used in late-stage clinical trials around the world.

"The ICH-GMP compliance is a milestone achievement for the Company," said MedReleaf CEO Neil Closner. "The ICH-GMP compliance supports our long-term, global growth plan and validates our commitment to quality control and pharmaceutical grade standards. We couldn't be more excited about the opportunities for MedReleaf to help the pharmaceutical industry more fully explore the benefits of medical cannabis and to bring our industry leading products to an increasing number of patients in Canada and around the world."

About MedReleaf

MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleafcanada.

Forward Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Final Long Form Prospectus dated May 30, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

SOURCE MedReleaf Corp.

For further information: Media contact: Diana McLachlan, Teneo Strategy, 647-334-8572; Investor contact: Dennis Fong, Investor Relations, [email protected], 416-283-9930

Related Links

www.medreleaf.com

